Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer
Briefings in Bioinformatics · 22.01.2024 · 25 (2)
DOI: 10.1093/bib/bbae071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 16.03.2024. Verfasst von Yitao Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Data Science, City University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The evolution of drug resistance leads to treatment failure and tumor progression. Intermittent androgen deprivation therapy (IADT) helps responsive cancer cells compete with resistant cancer cells in intratumoral competition. However, conventional IADT is population-based, ignoring the heterogeneity of patients and cancer. Additionally, existing IADT relies on pre-determined thresholds of prostate-specific antigen to pause and resume treatment, which is not optimized for individual patients. To address these challenges, we framed a data-driven method in two steps. First, we developed a time-varied, mixed-effect and generative Lotka–Volterra (tM-GLV) model to account for the heterogeneity of the evolution mechanism and the pharmacokinetics of two ADT drugs Cyproterone acetate and Leuprolide acetate for individual patients. Then, we proposed a reinforcement-learning-enabled individualized IADT framework, namely, I$^{2}$ADT, to learn the patient-specific tumor dynamics and derive the optimal drug administration policy. Experiments with clinical trial data demonstrated that the proposed I$^{2}$ADT can significantly prolong the time to progression of prostate cancer patients with reduced cumulative drug dosage. We further validated the efficacy of the proposed methods with a recent pilot clinical trial data. Moreover, the adaptability of I$^{2}$ADT makes it a promising tool for other cancers with the availability of clinical data, where treatment regimens might need to be individualized based on patient characteristics and disease dynamics. Our research elucidates the application of deep reinforcement learning to identify personalized adaptive cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Data Science, City University of Hong Kong, Hong Kong SAR, China.
- Department of Thoracic Oncology, Tongji Hospital, Huazhong University of Science and Technology, 430030, Wuhan, China.
- Department of Radiology, Tongji Hospital, Huazhong University of Science and Technology, 430030, Wuhan, China.
- Department of Electrical and Computer Engineering and the Center for Statistics and Machine Learning, Princeton University, 08544, NJ, U.S.A.
- Department of Integrated Mathematical Oncology and the Cancer Biology and Evolution Program, H. Lee Moffitt Cancer Center and Research Institute, 33612, FL, USA.
- Musketeers Foundation Institute of Data Science and the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Zitieren
APA
Lu, Y., Chu, Q., Li, Z., Wang, M., Gatenby, R., & Zhang, Q. (2024). Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer. Briefings in Bioinformatics, 25(2). https://doi.org/10.1093/bib/bbae071
Vancouver
Lu Y, Chu Q, Li Z, Wang M, Gatenby R, Zhang Q. Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer. Briefings in Bioinformatics. 2024;25(2). doi:10.1093/bib/bbae071
BibTeX
@article{Lu2024,
author = {Lu, Yitao and Chu, Qian and Li, Zhen and Wang, Mengdi and Gatenby, Robert and Zhang, Qingpeng},
title = {Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer},
journal = {Briefings in Bioinformatics},
year = {2024},
volume = {25},
number = {2},
doi = {10.1093/bib/bbae071}
}
EUVIMED